One or more of the required application components couldn’t be loaded. Please, refresh the page.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
6:28 PM
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BMY

Bristol-Myers Squibb Co

Last Close
Mar 14 • 04:00PM ET
59.01
Dollar change
-1.27
Percentage change
-2.11%
Healthcare • Drug Manufacturers - General • USA • NYSE
BMY - Stock Price Chart
Peers: PFE JNJ MRK LLY ABBV GILD AMGN AZN NVS
 | Held by: VTI VOO SCHD SPY IVV VTV XLV JEPI COWZ VYM
Scroll to Statements
IndexS&P 500 P/E- EPS (ttm)-4.43 Insider Own0.08% Shs Outstand2.03B Perf Week-3.40%
Market Cap119.75B Forward P/E9.63 EPS next Y6.13 Insider Trans0.31% Shs Float2.03B Perf Month5.09%
Income-8948.00M PEG- EPS next Q1.52 Inst Own79.99% Short Float1.51% Perf Quarter1.53%
Sales48.30B P/S2.48 EPS this Y486.75% Inst Trans3.14% Short Ratio2.57 Perf Half Y21.44%
Book/sh8.05 P/B7.33 EPS next Y-9.20% ROA-9.53% Short Interest30.57M Perf Year8.47%
Cash/sh5.35 P/C11.03 EPS next 5Y73.99% ROE-39.10% 52W Range39.35 - 63.33 Perf YTD4.33%
Dividend Est.2.46 (4.17%) P/FCF8.59 EPS past 5Y- ROI-13.70% 52W High-6.82% Beta0.41
Dividend TTM2.42 (4.10%) Quick Ratio1.15 Sales past 5Y18.97% Gross Margin56.80% 52W Low49.96% ATR (14)1.60
Dividend Ex-DateApr 04, 2025 Current Ratio1.25 EPS Y/Y TTM-214.24% Oper. Margin18.51% RSI (14)50.45 Volatility2.69% 2.61%
Employees34100 Debt/Eq3.13 Sales Y/Y TTM7.32% Profit Margin-18.53% Recom2.56 Target Price60.68
Option/ShortYes / Yes LT Debt/Eq3.00 EPS Q/Q-95.92% Payout59.82% Rel Volume1.00 Prev Close60.28
Sales Surprise6.70% EPS Surprise14.13% Sales Q/Q7.54% EarningsFeb 06 BMO Avg Volume11.88M Price59.01
SMA200.79% SMA501.98% SMA20013.82% Trades Volume11,894,296 Change-2.11%
Date Action Analyst Rating Change Price Target Change
Dec-16-24Upgrade Jefferies Hold → Buy $70
Dec-10-24Resumed BofA Securities Neutral $63
Nov-15-24Initiated Wolfe Research Peer Perform
Nov-13-24Upgrade Daiwa Securities Neutral → Outperform
Nov-12-24Upgrade Leerink Partners Market Perform → Outperform $73
Oct-25-24Downgrade Citigroup Buy → Neutral $75 → $55
Oct-17-24Initiated Bernstein Mkt Perform $56
Jul-29-24Downgrade Barclays Overweight → Equal Weight $41
Mar-11-24Downgrade Societe Generale Buy → Hold
Feb-06-24Downgrade Redburn Atlantic Buy → Neutral $77 → $54
Show Previous Ratings
Mar-14-25 06:59AM
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
(Business Wire)
05:30AM
Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
(The Wall Street Journal)
Mar-13-25 06:59AM
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
(Business Wire)
Mar-10-25 10:17PM
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
(Business Wire)
08:13PM
Analyst Report: Bristol-Myers Squibb Company
(Morningstar Research)
04:30PM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
04:30PM
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
(Investor's Business Daily)
Mar-08-25 02:20PM
Is Bristol-Myers Squibb Company (BMY) The Best Cheap Dividend Stock To Buy Right Now?
(Insider Monkey)
09:01AM
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
(Business Wire)
Mar-07-25 06:59AM
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
(Business Wire)
Mar-03-25 04:16PM
Bristol Myers Squibb Announces Dividend
(Business Wire)
Feb-28-25 07:00AM
Drug Stocks Are the New Safe Bet in a Shaky Market
(The Wall Street Journal)
Feb-26-25 02:25PM
Bristol-Myers Squibb Company (BMY): Top Stock to Buy from Dividend Stock Portfolio For Income
(Insider Monkey)
Feb-25-25 06:59AM
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
(Business Wire)
Feb-24-25 06:59AM
U.S. Food and Drug Administration Accepts Bristol Myers Squibbs Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
(Business Wire)
Feb-19-25 06:59AM
Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
(Business Wire)
10:05AM Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
Feb-18-25 10:05AM
Bristol Myers announces new five-year results from POETYK PSO trial
(TipRanks)
Feb-17-25 02:51AM
Why Bristol-Myers Squibb (BMY) Is Among the Best Drug Stocks to Buy Now
(Insider Monkey)
Feb-16-25 06:59AM
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
(Business Wire)
Feb-13-25 04:16PM
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
(Business Wire)
Feb-11-25 05:30AM
The Magnificent 7 Are So Last Year. Cash Cows Are the New Kings.
(The Wall Street Journal)
Feb-10-25 06:59AM
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
(Business Wire)
Feb-06-25 08:48PM
Analyst Report: Bristol-Myers Squibb Company
(Morningstar Research)
05:03PM
Bristol-Myers Squibb stock in focus on weak outlook
(Yahoo Finance Video)
04:03PM
Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook
(Investor's Business Daily)
11:27AM
Eli Lilly, Bristol Myers Squibb, Peloton: Market Minute
(Yahoo Finance Video)
06:59AM
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
(Business Wire)
Feb-04-25 09:50AM
Pfizer beats Q4, FY '24 earnings estimates, stock flat in early trading
(Yahoo Finance)
08:52AM
Pfizer beats Q4, FY '24 earnings estimates, stock flat in premarket trading
(Yahoo Finance)
08:52AM
Pfizer beats Q4, FY '24 earnings estimates, stock down slightly in premarket trading
(Yahoo Finance)
Feb-01-25 08:00AM
No One Knows How to Price AI Tools
(The Wall Street Journal)
04:01PM Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
Jan-31-25 04:01PM
Top Dividend Stocks Yielding As High As 5%: Fidelity
(Investor's Business Daily)
06:59AM
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
(Business Wire)
06:50AM
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
(Business Wire)
Jan-29-25 10:12PM
Why Bristol-Myers Squibb Company (BMY) Is the Best Blue Chip Stock to Buy Under $100?
(Insider Monkey)
03:50PM
Bristol-Myers Squibb (BMY): Cramer's Old-School Move for DeepSeek Market Jitters
(Insider Monkey)
Jan-28-25 03:00PM
Drugmakers Show Restraint on Price Increases in New Trump Era
(The Wall Street Journal)
Jan-25-25 10:02AM
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) Compared to Opdivo Monotherapy...
(Business Wire)
Jan-18-25 05:01PM
Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025?
(Insider Monkey)
08:20AM
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
(TipRanks)
Jan-17-25 11:10AM
Ozempic Among the Next Drugs Up for Medicare Price Negotiations
(The Wall Street Journal)
09:46AM
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
(Yahoo Finance)
Jan-13-25 03:13PM
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal
(The Wall Street Journal)
07:00AM
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
(GlobeNewswire)
Jan-10-25 12:50PM
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year
(ACCESSWIRE)
08:30AM
AI, vaccine distrust, & the future of healthcare: Novartis CEO
(Yahoo Finance Video)
Jan-06-25 09:00AM
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
(Business Wire)
Jan-03-25 06:59AM
Bristol Myers Squibb to Present at J.P. Morgans 43rd Annual Healthcare Conference
(Business Wire)
Dec-31-24 01:14PM
Is Bristol-Myers Squibb Company (BMY) Among the Best Pharma Dividend Stocks to Buy In 2024?
(Insider Monkey)
Dec-30-24 02:14PM
Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?
(Insider Monkey)
Dec-27-24 05:37PM
U.S. Food and Drug Administration Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo (nivolumab) Indications1,2
(Business Wire)
Dec-23-24 06:59AM
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
(Business Wire)
06:45AM
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite InstabilityHigh or Mismatch Repair Deficient Metastatic Colorectal Cancer
(Business Wire)
Dec-19-24 02:28PM
Bristol Myers Squibb Stock Earns 83 RS Rating
(Investor's Business Daily)
06:59AM
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
(Business Wire)
01:48AM
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
(PR Newswire)
Dec-18-24 09:00AM
insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS
(Business Wire)
08:45AM
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic and Anal Cancers
(GlobeNewswire)
Dec-17-24 06:30AM
Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline
(TipRanks)
Dec-11-24 04:17PM
Bristol Myers Squibb Announces Dividend Increase
(Business Wire)
Dec-09-24 05:45PM
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
(Business Wire)
Dec-07-24 05:30AM
Dividend Stocks Are Primed for a Comeback in 2025
(The Wall Street Journal)
Dec-03-24 08:00AM
AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M
(Business Wire)
Dec-02-24 07:44AM
Analyst Report: Bristol-Myers Squibb Company
(Morningstar Research)
Nov-26-24 06:59AM
Bristol Myers Squibb to Participate in Citis 2024 Global Healthcare Conference
(Business Wire)
Nov-22-24 04:09PM
AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback
(Investor's Business Daily)
11:30AM
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
(Investor's Business Daily)
Nov-19-24 06:59AM
Bristol Myers Squibbs Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
(Business Wire)
Nov-18-24 07:30AM
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
(Newsfile)
12:41AM
Analyst Report: Bristol-Myers Squibb Company
(Morningstar Research)
Nov-15-24 07:22PM
Analyst Report: Bristol-Myers Squibb Company
(Morningstar Research)
08:23AM
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite InstabilityHigh or Mismatch Repair Deficient Metastatic Colorectal Cancer
(Business Wire)
06:59AM
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
(Business Wire)
Nov-13-24 04:07PM
Avidity Bio Has Surged 416% This Year And That's Before Today's 'Game-Changing' News
(Investor's Business Daily)
Nov-12-24 04:05PM
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
(GlobeNewswire)
07:00AM
What the NFL Draft Can Teach Investors About Big Pharma
(The Wall Street Journal)
Nov-11-24 07:00PM
Analyst Report: Bristol-Myers Squibb Company
(Morningstar Research) +10.49%
04:32PM
S&P 500 Gains and Losses Today: Index Closes Above 6,000 on Post-Election Rally
(Investopedia)
04:04PM
Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'
(Investor's Business Daily)
03:45PM
AbbVie tumbles on drug test disappointment, Bristol-Myers gains
(Yahoo Finance Video)
10:12AM
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
(Investor's Business Daily)
09:39AM
AbbVie Stock Slides on Schizophrenia Drug Study Failure
(The Wall Street Journal)
06:59AM
Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
(Business Wire)
Nov-08-24 09:34AM
Analyst Report: Bristol-Myers Squibb Company
(Morningstar Research)
Nov-05-24 05:00PM
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
(Business Wire)
Nov-01-24 03:07PM
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
(Investor's Business Daily)
Oct-31-24 04:16PM
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
(Business Wire) +5.91%
04:12PM
Bristol Myers Screams To A Year-High After Walloping Profit Expectations
(Investor's Business Daily)
02:43PM
Analyst Report: Bristol-Myers Squibb Company
(Morningstar Research)
10:03AM
Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
(Yahoo Finance Video)
07:12AM
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance
(Investor's Business Daily)
06:59AM
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
(Business Wire)
Oct-29-24 11:17AM
Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure
(Yahoo Finance)
Oct-28-24 06:59AM
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
(Business Wire)
Oct-26-24 07:00AM
Pfizers Activist Battle Might Fizzlebut Its Stock Probably Wont
(The Wall Street Journal)
Oct-16-24 04:21PM
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.
(Investor's Business Daily)
Oct-15-24 06:09PM
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
(Investor's Business Daily)
Oct-14-24 09:59PM
Jim Cramer on Bristol-Myers Squibb Company (BMY): 'I Think It's A Great Time To Consider Buying This One'
(Insider Monkey)
Oct-07-24 05:30AM
Old Drug Repurposed for Schizophrenia Could Reap Alzheimers Windfall
(The Wall Street Journal)
Oct-03-24 05:35PM
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
(Business Wire)
01:11PM
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
(Investor's Business Daily)
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Institutional Ownership

VANGUARD GROUP INC9.37%
BlackRock, Inc.7.77%
JPMORGAN CHASE & CO4.73%
STATE STREET CORP4.69%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC2.97%
Capital International Investors2.26%
GEODE CAPITAL MANAGEMENT, LLC2.19%
NORGES BANK1.73%
AMERIPRISE FINANCIAL INC1.58%
FMR LLC1.53%
Income Statement • Balance Sheet • Cash Flow

Data

Timeframe

PeriodTTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period End Date—12/31/202412/31/202312/31/202212/31/202112/31/202012/31/201912/31/2018
Period Length12 Months12 Months12 Months

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.

Learn more
Total Revenue
48,300.0048,300.0045,006.00
Cost of Goods Sold Incl. D&A
20,868.0020,868.0019,649.00
Gross Profit
27,432.0027,432.0025,357.00
Selling, General and Administrative Excl. Other
18,494.0017,774.0016,885.00
Research and Development
10,130.009,782.009,207.00
Other Operating Expense
0.000.000.00
Operating Income
8,938.009,658.008,472.00
Interest Expense
1,947.001,947.001,166.00
Unusual Expense
17,513.0018,154.001,056.00
Net Income Before Taxes
-8,379.00-8,379.008,440.00
Income Taxes
554.00554.00400.00
Consolidated Net Income
-8,933.00-8,933.008,040.00
Net Income From Continuing Operations
-8,948.00-8,948.008,025.00
Net Income
-8,948.00-8,948.008,025.00
EPS (Recurring)
1.631.854.22
EPS (Basic, Before Extraordinaries)
-4.43-4.413.88
EPS (Diluted)
-4.43-4.413.86
EBITDA
18,489.0019,309.0018,283.00
Price To Earnings Ratio
-13.33-13.33-15.59
Price To Sales Ratio
2.392.372.37
Gross Margin
56.8056.8056.34
Operating Margin
18.5120.0018.82
Net Margin
-18.53-18.5317.83
Shares Outstanding
2,029.002,029.002,021.00
Market Capitalization
119,749.58119,749.58113,699.77
values in Millions, USD
Insider Trading Volume
MarAprMayJunJulAugSepOctNovDec25FebMar0.0055.00K110.00K165.00K220.00KUSD Trades Volume$32.00$40.00$48.00$56.00$64.00● Close Price
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Plenge Robert MEVP, Chief Research OfficerMar 10 '25Option Exercise0.0011,255020,148Mar 12 09:39 PM
Meyers Gregory ScottEVP, Chief Digital & Tech Off.Mar 10 '25Option Exercise0.0023,150026,937Mar 12 09:37 PM
Shanahan KarinEVP, Glob. Prod. Dev. & SupplyMar 10 '25Option Exercise0.0020,423022,339Mar 12 09:35 PM
Lenkowsky AdamEVP, Chief Commercial OfficerMar 10 '25Option Exercise0.0016,684020,017Mar 12 09:34 PM
Poole Ahn AmandaEVP, Chief People OfficerMar 10 '25Option Exercise0.007,16408,546Mar 12 09:32 PM
LEUNG SANDRAEVP, General CounselMar 10 '25Option Exercise0.0048,7180386,496Mar 12 09:32 PM
Hoch LynellePresident, Cell Therapy Org.Mar 10 '25Option Exercise0.007,44607,920Mar 12 09:31 PM
Holzer Phil MSVP and ControllerMar 10 '25Option Exercise0.007,140017,870Mar 12 09:31 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Mar 10 '25Option Exercise0.0044,098099,040Mar 12 09:30 PM
Gallman CariEVP, Corporate AffairsMar 10 '25Option Exercise0.007,588011,626Mar 12 09:29 PM
Elkins David VEVP, Chief Financial OfficerMar 10 '25Option Exercise0.0069,5170252,608Mar 12 09:28 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerMar 10 '25Option Exercise0.0060,0340152,898Mar 12 09:27 PM
Hickey BenjaminPresident, RayzeBio Org.Mar 01 '25Option Exercise0.003,286010,419Mar 04 05:44 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerFeb 20 '25Buy55.052,000110,096104,626Feb 21 07:09 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Feb 14 '25Buy54.841,823100,00063,932Feb 19 07:19 PM
Hickey BenjaminPresident, RayzeBio Org.Feb 01 '25Option Exercise0.0010,078010,858Feb 04 07:05 PM
Meyers Gregory ScottEVP, Chief Digital & Tech Off.Feb 01 '25Option Exercise0.002,54307,829Feb 04 07:04 PM
Holzer Phil MSVP and ControllerNov 04 '24Sale55.6270038,93011,760Nov 05 05:53 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerNov 01 '24Option Exercise0.002,9640104,169Nov 05 05:42 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Nov 01 '24Buy54.671,830100,05562,109Nov 05 05:41 PM
Holzer Phil MOfficerNov 04 '24Proposed Sale55.6270038,930Nov 04 11:20 AM
Gallman CariEVP, Corporate AffairsOct 02 '24Option Exercise0.004,55806,667Oct 03 06:33 PM
Gallman CariEVP, Corporate AffairsAug 01 '24Option Exercise0.001,06102,493Aug 05 06:01 PM
Shanahan KarinEVP, Glob. Prod. Dev. & SupplyApr 01 '24Option Exercise0.003,30606,532Apr 02 06:45 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.